<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(17)</volume><submitter>Graff J</submitter><funding>Swiss National Science Foundation</funding><pubmed_abstract>A series of derivatives of the substrate amino acid l-tryptophan have been investigated for inhibition of the L-type amino acid transporter LAT1 (SLC7A5), which is an emerging target in anticancer drug discovery. Of the four isomeric 4-, 5-, 6-, or 7-benzyloxy-l-tryptophans, the 5-substituted derivative was the most potent, with an IC&lt;sub>50&lt;/sub> of 19 μM for inhibition of [&lt;sup>3&lt;/sup> H]-l-leucine uptake into HT-29 human colon carcinoma cells. The replacement of the carboxy group in 5-benzyloxy-l-tryptophan by a bioisosteric tetrazole moiety led to a complete loss in potency. Likewise, the corresponding tetrazolide derived from l-tryptophan itself was found to be neither a substrate nor an inhibitor of the transporter. Increasing the steric bulk at the 5-position, while reasonably well tolerated in some cases, did not result in an improvement in potency. At the same time, none of these derivatives was found to be a substrate for LAT1-mediated transport.</pubmed_abstract><journal>ChemMedChem</journal><pagination>e202200308</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9545129</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Evaluation of l-Tryptophan Derivatives as Inhibitors of the l-Type Amino Acid Transporter LAT1 (SLC7A5).</pubmed_title><pmcid>PMC9545129</pmcid><pubmed_authors>Keller C</pubmed_authors><pubmed_authors>Singer S</pubmed_authors><pubmed_authors>Hartmann M</pubmed_authors><pubmed_authors>Graff J</pubmed_authors><pubmed_authors>Altmann KH</pubmed_authors><pubmed_authors>Sadurni A</pubmed_authors><pubmed_authors>Rubin M</pubmed_authors><pubmed_authors>Canivete Cuissa IA</pubmed_authors><pubmed_authors>Muller J</pubmed_authors><pubmed_authors>Gertsch J</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Evaluation of l-Tryptophan Derivatives as Inhibitors of the l-Type Amino Acid Transporter LAT1 (SLC7A5).</name><description>A series of derivatives of the substrate amino acid l-tryptophan have been investigated for inhibition of the L-type amino acid transporter LAT1 (SLC7A5), which is an emerging target in anticancer drug discovery. Of the four isomeric 4-, 5-, 6-, or 7-benzyloxy-l-tryptophans, the 5-substituted derivative was the most potent, with an IC&lt;sub>50&lt;/sub> of 19 μM for inhibition of [&lt;sup>3&lt;/sup> H]-l-leucine uptake into HT-29 human colon carcinoma cells. The replacement of the carboxy group in 5-benzyloxy-l-tryptophan by a bioisosteric tetrazole moiety led to a complete loss in potency. Likewise, the corresponding tetrazolide derived from l-tryptophan itself was found to be neither a substrate nor an inhibitor of the transporter. Increasing the steric bulk at the 5-position, while reasonably well tolerated in some cases, did not result in an improvement in potency. At the same time, none of these derivatives was found to be a substrate for LAT1-mediated transport.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2024-10-19T08:49:48.805Z</modification><creation>2024-10-19T08:49:48.805Z</creation></dates><accession>S-EPMC9545129</accession><cross_references><pubmed>35895286</pubmed><doi>10.1002/cmdc.202200308</doi></cross_references></HashMap>